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jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ jcc as eVenous thromboembolism (VTE), which includes deep vein
thrombosis (DVT) and pulmonary embolism (PE), is the third most
common cardiovascular disorder worldwide, having an estimated
annual incidence of 0.1% and affecting 2–5% of the world’s
population during their lifetime. It has been previously reported
that the incidence rate of DVT after orthopedic surgery is relatively
lower among Japanese patients than among Caucasian patients
[1]. However, until recently, there had been no systematic studies
on the incidence rate of VTE, particularly in the Japanese
population [2]. As VTE is drawing more attention, a systematic
study on its treatment was published using data from the Japan
VTE Treatment Registry (JAVA) in 2014 [3]. Although aggressive
therapies were performed in the acute phase of PE, chronic
anticoagulation therapy was not as strongly recommended as the
European and US anticoagulation guidelines did.
PE treatment comprises anticoagulation, reperfusion, and
inferior vena cava (IVC) ﬁlter placement. Reperfusion therapy
includes systemic ﬁbrinolysis, catheter-directed techniques, and the
surgical removal of emboli. While remarkable progress has been
made with interventional devices, anticoagulation therapy has also
been developing since non-vitamin K antagonist oral anticoagulants
(NOACs) were approved for VTE treatment. Phase III trials
investigating the efﬁcacy of NOACs such as apixaban, dabigatran,
edoxaban, and rivaroxaban, for the treatment of VTE have been
published [4–9]. In Japan, three NOACs, namely, edoxaban,
rivaroxaban, and apixaban have been approved for VTE treatment
to date. Clinical trials have proved that these NOACs are not inferior
to conventional treatments, which include enoxaparin, unfractio-
nated heparin, and warfarin. Enoxaparin is not widely used in Japan.
Instead, fondaparinux, which is a synthetic pentasaccharide with
anti-Xa activity, has been more commonly used in Japan. Clinical
trial results suggested that NOACs were safer than warfarin with
target prothrombin time-international normalization ratio (INR)
2–3 in terms of having lower incidence rates of major bleeding
events, such as intracranial bleeding [10]. From the standpoint of
long-term treatment planning, NOACs are expected to be a better
choice than warfarin, when their price becomes more competitive
with warfarin. This is because we can expect reliable efﬁcacy and a
reduced need for blood test monitoring [10]. Although there have
been many studies on NOACs versus the aforementioned conven-
tional therapies, the best NOAC for the treatment of PE and VTE has
not been well studied.DOI of original article: http://dx.doi.org/10.1016/j.jccase.2016.03.020
http://dx.doi.org/10.1016/j.jccase.2016.06.009
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the use of rivaroxaban showed a better outcome as compared to
edoxaban in an older female patient with DVT complicated by PE and
an invaginated thrombus via a patent foramen ovale (PFO)
[11]. Although this is a single case report, it provides some
interesting points regarding patients with PE and PFO. How
aggressive should we be in terms of performing invasive procedures
such as catheter-directed thrombectomy or IVC ﬁlter placement?
Should we administer systemic ﬁbrinolysis therapy? How and
which medications should we use for initial anticoagulation therapy
and for maintaining the anticoagulation status? How should we
treat patients with PFO to prevent stroke? Such questions must
always be answered when caring for patients with PE and PFO.
The treatment for PE is time-sensitive. It is of the most
importance to detect PE and keep hemodynamic stability with
pressors and inotropes. At the same time, we need to evaluate the
necessity of surgical or catheter-guided intervention such as
thrombectomy and IVC ﬁlter placement. The initiation of antic-
oagulation is the most important step not only from the standpoint
of acute treatment but also for chronic management. Intravenous
administration of heparin followed by oral warfarin has been and
still is the gold standard therapy for the treatment of PE. In the USA
and European countries, subcutaneous enoxaparin injection is also
a possible treatment choice. Although treatment with heparin and
warfarin is well established and familiar to many clinicians, there
are a few reasons for the possible superiority of NOACs. First,
NOACs such as rivaroxaban have more stable pharmacokinetics
proﬁle than warfarin and pharmacodynamics. Second, some
patients with the use of heparin, low-molecular weight heparin,
or even fondaparinux are resistant to these drugs because their
anticoagulant effects are mediated by antithrombin III. Moreover,
these drugs have a potential to induce heparin-induced thrombo-
cytopenia/thrombosis (HITT). HITT is a complicated and risky
condition to induce clot formation even when platelet count is low.
HITT might be recognized as the recurrence of PE. If the
anticoagulant effect of NOACs appears immediately after their
intake, they might provide us with solutions to the aforementioned
problems that we have encountered in actual clinical settings.
The answer to the question ‘‘Which NOAC is the best for PE and
VTE’’ remains uncertain. There have been no randomized
controlled trials comparing the efﬁcacy NOACs. This case report
by Dr. Chitose suggests that rivaroxaban was superior to edoxaban,
but this might simply have been due to the dosage difference as it
was pointed out by the author. In Japan, the dosage of rivaroxaban
approved for VTE treatment in the initial 3 weeks is twice as much reserved.
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Fig. 1.
The decision tree on management of a patent foramen ovale (PFO)
patient based on presence of cryptogenic stroke or deep venous
thromboembolism (DVT).
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ﬁbrillation. Contrarily, there is basically no dosage difference of
edoxaban for these two clinical indications. It may be an interesting
idea to switch from one NOAC to another if the ﬁrst NOAC does not
show any clinical efﬁcacy. Although all NOACs approved for PE in
Japan show anti-Xa inhibiting activities, subtle differences may exist
among them that could affect their efﬁcacies depending on the
patient’s biological condition. After the acute phase of PE, it is
important to continue anticoagulation therapy for at least 3 months.
Therefore, compliance and adherence are crucial to prevent
recurrence of VTE just like stroke prevention for atrial ﬁbrillation
(AF) patients. It has been reported that actual adherence rates are
much lower than those of clinical trials and that NOACs may still be
beneﬁcial in maintaining higher adherence rates compared with
warfarin although the real world report did not support this idea in
terms of stroke prevention for AF patients [12].
In this report, the patient’s echocardiogram revealed an
invaginated thrombus via PFO. Studies on PFO are gaining clinical
interest because PFO is recognized as a possible cause of embolic
stroke when its cause is undetermined. The foramen ovale does not
close in approximately 25% of the general population although it
usually does not cause any clinical problems [13]. If there is a
paradoxical right to left shunt and a source of emboli, an embolic
stroke, which is a cryptogenic stroke, could occur. DVT is often
considered a risk factor for cryptogenic stroke. It has been reported
that not only DVTs in the extremities but also DVTs in the pelvic
veins can be a source of embolism [14]. Although PFO without any
history of stroke is not an indication for anticoagulation, the latest
guidelines from the American Heart Association and American
Stroke Association recommend that anticoagulation should be
initiated for patients with cryptogenic stroke and DVTs [15]. His-
tory of stroke and presence of DVTs are key points to the
management of PFO patients (Fig. 1). According to the latest
guidelines, aspirin is still the ﬁrst-line treatment for cryptogenic
stroke without DVTs; however, there are several ongoing clinical
trials comparing the efﬁcacy of NOACs with aspirin, such as
NAVIGATE-ESUS and RE-SPECT ESUS trials (clinicaltrials.gov).
In conclusion, we expect NOACs to provide us with several options
for treatment and they may improve the treatment effect, while
heparin followed by warfarin is still the standard of care. We should
carefully observe emerging differences in the efﬁcacies of NOACs
among various regions and countries [16]. Although published data
from large trials should be appreciated, clinical physicians should
appropriately apply these data according to each patient’s proﬁle.
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